The latest in peptides — new research, FDA moves, safety signals, and what's changing for the people who use them. Every story links back to where it came from.
The GLP-1 receptor agonist efficacy ladder keeps climbing: semaglutide (~15% mean weight loss), the dual GIP/GLP-1 agonist tirzepatide (~21%), and triple agonists such as retatrutide (glucagon/GIP/GLP-1) reporting even greater reductions in Phase 2. The 2026 pipeline is crowded with next-generation candidates aiming for greater efficacy, oral delivery, and muscle preservation.
On July 23–24, 2026, the FDA's Pharmacy Compounding Advisory Committee recommended adding six of seven reviewed peptides (BPC-157, KPV, TB-500, MOTS-c, Epitalon, Semax) to the Section 503A Bulks List and rejected Emideltide/DSIP. The vote is advisory only — not a final FDA decision and not legal authorization to compound. FDA must still complete formal notice-and-comment rulemaking (typically 12–24 months) before any change in legal status.
This journal listing includes several articles touching on obesity pharmacotherapy, most notably a systematic review and meta-analysis of subcutaneous semaglutide's effects on weight loss and inflammatory markers in adults with overweight or obesity without diabetes. Additional items examine GLP-1 receptor agonists from a rheumatological perspective and self-medication with GLP-1 drugs among Brazilian adults. The listing also covers broader obesity research, including bariatric surgery positioning and epidemiological studies.
New research suggests that semaglutide reduces the risk of major adverse cardiovascular events (MACE) not only through weight loss but also by lowering systemic inflammation. A study of over 17,000 patients found that reductions in the inflammatory biomarker hs-CRP accounted for roughly 28% of the drug's cardiovascular benefit. This indicates that semaglutide's mechanism for heart protection involves direct anti-inflammatory effects independent of glycemic control or body weight reduction.
Medical experts emphasize that while the usage of GLP-1 receptor agonists like Wegovy is surging, these medications are most effective when combined with lifestyle modifications such as diet and exercise. Recent data indicates that approximately 1 in 8 U.S. adults are currently utilizing these treatments, yet specialists warn against viewing the prescription as a standalone cure. Research indicates that integrating healthy habits maximizes weight loss and improves long-term health outcomes.
This article examines the cultural phenomenon of the 'peptide craze,' specifically focusing on the off-label use of GLP-1 receptor agonists like semaglutide and tirzepatide for weight loss and wellness. It discusses how the demand for these injectable diabetes drugs has shifted the public perception of risk, leading individuals to seek out unregulated sources. The piece highlights the disconnect between the medical necessity of these drugs and their casual use for cosmetic or lifestyle enhancement.
This article discusses the history and flaws of the Body Mass Index (BMI) while noting that the metric has become increasingly relevant due to the emergence of semaglutide weight loss drugs. It suggests that these new therapies are transforming the medical understanding and treatment of obesity, a condition historically defined by the imperfect BMI standard.
A new KFF survey highlights that rising healthcare costs are forcing Americans to cut back on basic necessities. The report cites the specific case of Priscilla Brown, a Type 2 diabetic who admits to rationing her insulin doses to afford expenses like gas. The financial strain is attributed to the expiration of enhanced Affordable Care Act tax credits, leading to higher premiums and difficult choices for enrollees.
A November 2025 New York Times explainer takes a skeptical consumer lens to the peptide-therapy craze, separating the few uses with reasonable evidence (topical GHK-Cu and Matrixyl-type peptides in skincare) from the largely unproven injectable and "biohacking" market (BPC-157, TB-500, epitalon, semax, selank). Dermatologists frame cosmetic peptides as "sidekicks, not hero ingredients," while endocrinologists warn that growth-hormone-releasing peptides like sermorelin and tesamorelin carry the same long-term risks as HGH — diabetes, certain cancers, and acromegaly. The piece notes that most longevity claims rest on cell-culture or animal data only, and that "research-grade" products have no quality controls.
A June 2025 Reuters investigation details a fast-growing "gray market" in which Americans import bulk semaglutide, tirzepatide, retatrutide, and cagrilintide powders from Chinese vendors — labeled as research materials — and reconstitute them into injectable weight-loss drugs at home for roughly one-tenth of the brand-name price. Buyers coordinate on Reddit and Telegram (one group, StairwayToGray, surpassed 21,000 members), pooling money for third-party purity testing. Eli Lilly and Novo Nordisk call the practice dangerous and illicit, and 38 state attorneys general asked the FDA to intervene. One profiled user overdosed after a self-dosing miscalculation, highlighting the absence of medical oversight.
Medetomidine and its active isomer dexmedetomidine ('dex') are rapidly replacing xylazine ('tranq') as adulterants in the illicit fentanyl supply. Reports from cities like Philadelphia indicate a massive surge in prevalence, rising from 29% to 87% of fentanyl samples within months. This shift complicates overdose reversal and causes severe health complications, including heart and brain damage and agonizing withdrawal symptoms.
The FDA's 2024-2025 updates to the Ozempic and Wegovy (semaglutide) prescribing information added warnings for ileus/intestinal blockage, pulmonary aspiration during anesthesia, and ongoing gastroparesis surveillance, reflecting accumulating postmarketing reports - including roughly 20 ileus reports with two deaths. A 2025 observational study found an increased gastroparesis incidence in semaglutide users versus a comparator weight-loss drug, and federal GLP-1 gastroparesis litigation (MDL 3094) has consolidated hundreds of claims. The label changes underscore that delayed gastric emptying - the drug's mechanism - has real downstream safety consequences that prescribers must manage.
In April 2025 Pfizer discontinued development of the oral GLP-1 receptor agonist danuglipron for chronic weight management after late-stage trials revealed a drug-induced liver injury (DILI) signal with elevated liver enzymes. The decision ended a years-long effort to field a small-molecule GLP-1 pill and came after an earlier once-daily formulation had already been shelved in 2023 for the same reason. The exit narrows the oral GLP-1 race to Lilly's orforglipron and Novo Nordisk's oral semaglutide, and it is a cautionary safety case for the broader peptide-therapeutics field on hepatotoxicity surveillance.
As of May 31, 2026, the FDA reported 990+ adverse-event reports tied to compounded semaglutide and 730+ for other compounded GLP-1 products, citing risks from unapproved, non-sterile, or misbranded copycat products. The agency reiterated that compounded versions lack an FDA-approved-quality assurance.
On April 14, 2025, the FDA warned consumers and healthcare providers not to use counterfeit Ozempic (semaglutide) 1 mg injection that had entered the US drug supply chain after Novo Nordisk reported several hundred suspect units. The agency flagged risks of wrong active ingredient, incorrect dose, and contamination, and advised the supply chain to quarantine and verify the implicated lot. The alert sits atop a broader body of evidence - including pharmacovigilance analyses of suspected-counterfeit semaglutide where ~89% of reported adverse drug reactions were classified as serious (vomiting, nausea, hypoglycemia) - underscoring that the GLP-1 boom has spawned a parallel counterfeit and illicit-compounding safety problem.
A systematic review and network meta-analysis of 39 studies (33,354 participants) assessed gastrointestinal adverse events of GLP-1 receptor agonists in non-diabetic patients with overweight or obesity. Nausea, vomiting, diarrhea, and constipation were the most common side effects. Orforglipron showed the highest nausea risk, followed by exenatide, tirzepatide, semaglutide, and liraglutide. The differing safety profiles can help clinicians tailor weight-loss therapy choices.
On July 23–24, 2026, the FDA's Pharmacy Compounding Advisory Committee recommended adding six of seven reviewed peptides (BPC-157, KPV, TB-500, MOTS-c, Epitalon, Semax) to the Section 503A Bulks List and rejected Emideltide/DSIP. The vote is advisory only — not a final FDA decision and not legal authorization to compound. FDA must still complete formal notice-and-comment rulemaking (typically 12–24 months) before any change in legal status.
The FDA has granted accelerated approval to Bristol Myers Squibb's iberdomide, marketed as Zenbexus, for relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab. As a first-in-class CELMoD agent, iberdomide is a cereblon-modulating peptide-like molecule that induces targeted protein degradation to eliminate cancer-driving proteins. The approval was supported by Phase 3 data showing a statistically significant improvement in minimal residual disease-negative complete response rates compared to standard care.
Novo Nordisk has announced two major regulatory milestones in the European Union. The company received approval for an oral version of its weight management drug Wegovy, as well as a new 7.2 mg dose pen. Additionally, the company is taking legal action against Eli Lilly regarding misleading GLP-1 advertising campaigns.
The FDA has granted accelerated approval to Novo Nordisk’s Wegovy (semaglutide) for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis. This decision is based on Phase 3 data from the ESSENCE trial, where the drug significantly outperformed placebo in resolving liver inflammation and improving scarring. Wegovy is now the first GLP-1 receptor agonist approved for this liver condition.
The FDA has approved Novo Nordisk's once-weekly GLP-1 receptor agonist Ozempic (semaglutide) to improve glycemic control in adults with type 2 diabetes. Based on the SUSTAIN Phase 3a clinical trial program involving over 8,000 adults, the drug demonstrated superior A1c reductions compared to sitagliptin and exenatide extended-release, as well as significant weight loss as a secondary benefit. The drug will be available in 0.5 mg and 1 mg pre-filled pen doses.
Medivir has received a Notice of Allowance from the US Patent and Trademark Office for a patent covering the combination of its peptide prodrug fostrox and lenvatinib for treating liver cancers. This approval strengthens the company's intellectual property position in the US market, extending potential market exclusivity for this combination therapy until at least 2041.
An analysis of rate filings from small group insurers indicates that small businesses may face a median premium increase of 14% in 2027. The filings identify rising healthcare costs and increased utilization as primary factors, specifically highlighting the financial impact of specialty drugs. Insurers explicitly cite GLP-1 medications as a significant driver behind these escalating costs and subsequent premium hikes.
Novo Nordisk's U.S. news portal highlights several key developments regarding its peptide-based portfolio. The company is actively challenging Eli Lilly's advertising campaigns regarding GLP-1 therapies, signaling ongoing market competition. Additionally, Novo Nordisk reported positive Phase 3 results for its hemophilia A drug denecimig and expanded access to Wegovy for Medicare beneficiaries.
Olympia Pharmaceuticals is promoting its services as both a 503B FDA-registered outsourcing facility and an affiliated 503A compounding pharmacy. The company offers a range of injectable products, including peptide and nutrient blends, targeting weight management, longevity, and sexual health. Their business model focuses on providing office-use medications to physicians and direct prescription fulfillment to patients.
Stonegate Capital Partners has updated its coverage on Burcon Nutrascience Corporation, highlighting the company's transition into commercial utilization with increased production of plant-based proteins. The report notes that demand for Burcon's pea, canola, and fava proteins is being driven by the growing market for GLP-1-related nutrition products, where high protein content and functional taste are critical for formulation.
This article serves as a STAT news hub covering Amgen Inc., featuring a collection of headlines regarding the company's business and clinical pipeline. It specifically highlights Amgen's position in the competitive GLP-1 weight loss drug market, referencing their candidate MariTide (AMG 133). The coverage notes clinical trial outcomes, including high discontinuation rates in mid-stage studies and subsequent dosing adjustments.
This STAT Plus report investigates the evolution of the telehealth industry from a platform for increasing healthcare access to a primary vehicle for direct-to-consumer drug sales. It highlights how companies like Hims and Ro initially disrupted the market with erectile dysfunction treatments and are now capitalizing on the high demand for weight loss peptides. The article argues that this shift represents a broader consumerization of medicine, where virtual care serves as a marketing funnel for pharmaceutical products.
A case report published in Nature Communications suggests that the peptide derivative acetyl-DL-leucine (ADLL) may modify the progression of prodromal Parkinson's disease. In two patients with isolated REM sleep behavior disorder (iRBD), long-term treatment with ADLL not only reduced sleep symptoms but also appeared to reverse the loss of dopamine transporter binding in the brain. These findings indicate that ADLL could potentially slow or stabilize neurodegeneration associated with Parkinson's.
Data from the INHALE-1 trial presented at the American Diabetes Association Scientific Sessions indicates that MannKind’s Technosphere insulin (Afrezza) is a safe and effective alternative to injected rapid-acting analogs for children and adolescents with diabetes. The study found that the inhaled formulation achieved similar HbA1c reductions to standard care while resulting in less weight gain and higher patient satisfaction scores.
A new Lancet commission report proposes reframing obesity as a distinct disease spectrum divided into 'preclinical' and 'clinical' stages, moving beyond reliance on BMI. This diagnostic shift aligns with recent FDA guidance prioritizing pharmacological treatments, such as GLP-1 receptor agonists, over lifestyle changes alone. The reclassification aims to improve clinical decision-making regarding which patients require medical intervention for organ dysfunction caused by excess adiposity.
STAT columnist Adam Feuerstein analyzes new clinical data for ImmunityBio's cancer drug Anktiva, arguing that the results contradict founder Patrick Soon-Shiong's claims of survival benefits in advanced lung cancer patients. The article highlights the drug's modest commercial performance for bladder cancer and notes the recent approval of a superior competitor by Johnson & Johnson.
Opus Genetics is advancing clinical programs for inherited retinal diseases, specifically targeting LCA5 and BEST1 mutations. The company recently announced FDA alignment on a Phase 3 trial design for OPGx-LCA5 and provided a timeline for OPGx-BEST1 results. These gene therapy programs aim to address the underlying genetic causes of rare vision loss.
A secondary analysis of a long-term clinical trial published in the Annals of Internal Medicine indicates that bariatric surgery outperforms medical therapy, including GLP-1 drugs, for treating type 2 diabetes and obesity across diverse income levels. The research found that surgery led to superior outcomes in blood glucose control, weight loss, and diabetes remission regardless of social determinants of health. While acknowledging the rapid evolution of more potent obesity medications, the authors maintain that metabolic surgery remains an effective and underutilized durable solution.
The GLP-1 receptor agonist efficacy ladder keeps climbing: semaglutide (~15% mean weight loss), the dual GIP/GLP-1 agonist tirzepatide (~21%), and triple agonists such as retatrutide (glucagon/GIP/GLP-1) reporting even greater reductions in Phase 2. The 2026 pipeline is crowded with next-generation candidates aiming for greater efficacy, oral delivery, and muscle preservation.
This journal listing includes several articles touching on obesity pharmacotherapy, most notably a systematic review and meta-analysis of subcutaneous semaglutide's effects on weight loss and inflammatory markers in adults with overweight or obesity without diabetes. Additional items examine GLP-1 receptor agonists from a rheumatological perspective and self-medication with GLP-1 drugs among Brazilian adults. The listing also covers broader obesity research, including bariatric surgery positioning and epidemiological studies.
New research suggests that semaglutide reduces the risk of major adverse cardiovascular events (MACE) not only through weight loss but also by lowering systemic inflammation. A study of over 17,000 patients found that reductions in the inflammatory biomarker hs-CRP accounted for roughly 28% of the drug's cardiovascular benefit. This indicates that semaglutide's mechanism for heart protection involves direct anti-inflammatory effects independent of glycemic control or body weight reduction.
Swedish biotech Oxcia has promoted Dr. Sandra Ekstedt to Preclinical Director to advance the development of OXC-201, a first-in-class oral inhibitor targeting the OGG1 enzyme. The drug candidate is designed to treat Idiopathic Pulmonary Fibrosis (IPF) by blocking the interaction between damaged DNA and OGG1, thereby preventing inflammation and fibrosis. Dr. Ekstedt, a specialist in respiratory diseases, will finalize the preclinical program and investigate the drug's ability to alleviate cough and improve lung function.
Nykode Therapeutics has released new preclinical and manufacturing data for VB10.NEO, an individualized neoantigen therapy. The results indicate that their DNA-based platform induces stronger and more durable T-cell responses compared to traditional peptide vaccines. Additionally, the company reported improvements in manufacturing scalability and timelines, positioning the asset for strategic partnerships.
A review in Nature Reviews Disease Primers examines the biological underpinnings and clinical management of nausea and vomiting of pregnancy (NVP) and hyperemesis gravidarum (HG). It highlights recent genetic advances implicating the hormone GDF15 and the protein IGFBP7 as key drivers of the condition, acting through receptors in the brainstem. These findings suggest a placental origin for the disease and offer potential targets for future therapeutic development.
Varró, Mándityné Huszka, Erdei, Mándoki and Mándity reported a continuous-flow solid-phase peptide synthesis platform that swaps toxic DMF/NMP for the greener solvent propylene carbonate. Published in Chemistry–Methods (May 2025), the method synthesized both α- and β-peptides at greater than 4-gram scale with good efficiency, pairing the throughput and automation advantages of continuous flow with a lower-toxicity, biodegradable solvent. The work tackles SPPS's chronic environmental weakness — huge volumes of hard-to-dispose polar aprotic solvents and a notoriously high Process Mass Intensity. As GLP-1-driven demand scales peptide manufacturing, greener high-throughput routes are becoming both a regulatory and a cost imperative.
On January 8, 2025, PolyPeptide Group announced a roughly €100 million investment to double solid-phase peptide synthesis (SPPS) capacity at its Malmö, Sweden plant, adding around 100 permanent jobs. The expansion is mainly tied to a long-standing GLP-1 customer agreement under one of the company's large commercial deals, with revenue contribution expected to begin in 2028. It reflects the global manufacturing crunch driven by GLP-1 agonist demand, which has outstripped existing peptide-API capacity and triggered comparable multi-hundred-million-euro build-outs at rivals such as Bachem and Lonza. Modular pre-built units were installed on-site during 2025 so existing production could keep running through the build-out.
Colston et al. clarified the molecular mechanism by which salcaprozate sodium (SNAC) — the absorption enhancer in oral semaglutide (Rybelsus) — lets peptides cross the gut epithelium. They show SNAC inserts into cell membranes and generates transient, fluid defects through which peptides like semaglutide slip. The work helps explain why oral semaglutide needs roughly 400 mg of SNAC for just 7–14 mg of peptide, and could inform next-generation oral peptide formulations beyond GLP-1s.
A denoising diffusion model from David Baker's Institute for Protein Design generates macrocyclic peptide binders against arbitrary protein targets. Tested on four targets, it produced nanomolar-affinity binders from fewer than 20 designs each, with crystal structures matching the computational models to within ~1.5 Å. Published in Nature Chemical Biology, the work signals that AI can now yield drug-like cyclic peptides on demand.
Researchers developed AAGP, a machine learning tool designed to predict potential anti-aging peptides. By analyzing over 4,000 physicochemical and compositional features, the model achieved high accuracy in distinguishing anti-aging peptides from other random or antimicrobial sequences. This computational approach aims to accelerate the discovery of peptide therapies for age-related decline.
This is an FDA UNII database record for gonadorelin, the synthetic decapeptide form of gonadotropin-releasing hormone (GnRH/LHRH). It lists the substance's unique identifier (9O7312W37G), chemical sequence, and various synonyms. The record notes that UNII availability does not imply regulatory review or approval.
The peptides mentioned most often in our news coverage.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.